Skip to main content
Top
Published in: Current Treatment Options in Gastroenterology 4/2015

01-12-2015 | Stomach (C Howden, Section Editor)

Gastric Hypersecretory States: Investigation and Management

Authors: Jennifer Phan, MD, Jihane N. Benhammou, MD, Joseph R. Pisegna, MD

Published in: Current Treatment Options in Gastroenterology | Issue 4/2015

Login to get access

Opinion statement

Hypersecretory conditions affecting the stomach account for significant morbidity and mortality manifested in some cases with peptic ulcer, gastrointestinal hemorrhage, and/or gastroesophageal reflux disease (GERD). The diagnosis of gastric acid hypersecretory states can be challenging and relies on the use of quantitative assays to measure gastric acid secretion and serum gastrin. The most common etiology for hypergastrinemia is the use of potent gastric acid inhibitors such as the proton pump inhibitors. The differential diagnosis of this condition is of critical importance, and will dictate management decisions. Conditions such as atrophic gastritis are relatively benign and can lead to hypergastrinemia without the presence of gastric acid hypersecretion. Zollinger-Ellison syndrome, on the other hand, causes hypergastrinemia with profound gastric acid hypersecretion [1]. More common causes of hypergastrinemia include gastric outlet obstruction, ileus, and chronic renal failure [2]. In most cases, proton pump inhibitors will be used to manage these conditions. In some instances, surgical therapy may be required. This chapter will review the important clinical causes of gastric acid hypersecretion and provide insights to the best medical management options to better care for patients with these disorders.
Literature
1.
go back to reference Metz DC, Ferron GM, Paul J, Turner MB, Soffer E, Pisegna JR, et al. Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study. J Clin Pharm. 2002;42:512–9.CrossRef Metz DC, Ferron GM, Paul J, Turner MB, Soffer E, Pisegna JR, et al. Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study. J Clin Pharm. 2002;42:512–9.CrossRef
2.
go back to reference Benhammou J, Jacob N, Vu J, Ohning GV, Germano PM, Waschek J, et al. Gastroenterology. 2015;148((4) Suppl 1):S-734.CrossRef Benhammou J, Jacob N, Vu J, Ohning GV, Germano PM, Waschek J, et al. Gastroenterology. 2015;148((4) Suppl 1):S-734.CrossRef
4.
go back to reference Zeng N, Athmann C, Kang T, Lyu RM, Walsh JH, Ohning GV, et al. PACAP type I receptor activation regulates ECL cells and gastric acid secretion. J Clin Invest. 1999;104(10):1383–91. Zeng N, Athmann C, Kang T, Lyu RM, Walsh JH, Ohning GV, et al. PACAP type I receptor activation regulates ECL cells and gastric acid secretion. J Clin Invest. 1999;104(10):1383–91.
5.
go back to reference Metz DC, Comer GM, Soffer E, Forsmark CE, Cryer B, Chey W, et al. Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Ther. 2006;23(3):437–44.CrossRefPubMed Metz DC, Comer GM, Soffer E, Forsmark CE, Cryer B, Chey W, et al. Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Ther. 2006;23(3):437–44.CrossRefPubMed
6.
go back to reference Metz DC, Pisegna JR, Fishbeyn VA, Benya RV, Jensen RT. Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome. World J Surg. 1993;17(4):468–80.CrossRefPubMed Metz DC, Pisegna JR, Fishbeyn VA, Benya RV, Jensen RT. Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome. World J Surg. 1993;17(4):468–80.CrossRefPubMed
7.
go back to reference Strader DB, Benjamin SB, Orbuch M, Lubensky TA, Gibril F, Weber C, et al. Esophageal function and occurrence of Barrett’s esophagus in Zollinger-Ellison syndrome. Digestion. 1995;56(5):347–56.CrossRefPubMed Strader DB, Benjamin SB, Orbuch M, Lubensky TA, Gibril F, Weber C, et al. Esophageal function and occurrence of Barrett’s esophagus in Zollinger-Ellison syndrome. Digestion. 1995;56(5):347–56.CrossRefPubMed
8.
go back to reference Pisegna J, Holtmann G, Howden CW, Katelaris PH, Sharma P, Spechler S, et al. Esophageal complications and consequences of persistent gastro-esophageal reflux disease. Aliment Pharmacol Ther. 2004;20(9):47–56.CrossRefPubMed Pisegna J, Holtmann G, Howden CW, Katelaris PH, Sharma P, Spechler S, et al. Esophageal complications and consequences of persistent gastro-esophageal reflux disease. Aliment Pharmacol Ther. 2004;20(9):47–56.CrossRefPubMed
9.
go back to reference Pisegna JR. The effect of Zollinger-Ellison syndrome and neuropeptide-secreting tumors on the stomach. Curr Gastroenterol Rep. 1999;1(6):511–7.CrossRefPubMed Pisegna JR. The effect of Zollinger-Ellison syndrome and neuropeptide-secreting tumors on the stomach. Curr Gastroenterol Rep. 1999;1(6):511–7.CrossRefPubMed
10.
go back to reference Kohan E, Oh D, Wang H, Hazany S, Ohning G and Pisegna JR. Duodenal bulb mucosa with hypertrophic gastric oxyntic heterotopia in patients with Zollinger Ellison syndrome. Diagn Ther Endosc. 2009. Kohan E, Oh D, Wang H, Hazany S, Ohning G and Pisegna JR. Duodenal bulb mucosa with hypertrophic gastric oxyntic heterotopia in patients with Zollinger Ellison syndrome. Diagn Ther Endosc. 2009.
11.
go back to reference Webster MW, Barnes EL, Stremple JF. Serum gastrin levels in the differential diagnosis of recurrent peptic ulceration due to retained gastric antrum. Am J Surg. 1978;135(2):248–52.CrossRefPubMed Webster MW, Barnes EL, Stremple JF. Serum gastrin levels in the differential diagnosis of recurrent peptic ulceration due to retained gastric antrum. Am J Surg. 1978;135(2):248–52.CrossRefPubMed
12.
go back to reference Fisher JC, Masiakos PT, Oviedo J, Burch M, Kondi ES, Wolfe MM, et al. Gastric outlet obstruction as a consequence of a duodenal web masquerading as gastrinoma in an adult. Curr Surg. 2003;60(6):602–6.CrossRefPubMed Fisher JC, Masiakos PT, Oviedo J, Burch M, Kondi ES, Wolfe MM, et al. Gastric outlet obstruction as a consequence of a duodenal web masquerading as gastrinoma in an adult. Curr Surg. 2003;60(6):602–6.CrossRefPubMed
13.
go back to reference Chuang CH, Sheu BS, Yang HB, Kao AW, Cheng HC, Yao WJ. Hypergastrinemia after Helicobacter pylori infection is associated with bacterial load and related inflammation of the oxyntic corpus mucosa. J Gastroenterol Hepatol. 2004;19(9):988–93.CrossRefPubMed Chuang CH, Sheu BS, Yang HB, Kao AW, Cheng HC, Yao WJ. Hypergastrinemia after Helicobacter pylori infection is associated with bacterial load and related inflammation of the oxyntic corpus mucosa. J Gastroenterol Hepatol. 2004;19(9):988–93.CrossRefPubMed
14.
go back to reference McGowan CC, Cover TL, Blaser MJ. Helicobacter pylori and gastric acid: biological and therapeutic implications. Gastroenterology. 1996;110:926–38.CrossRefPubMed McGowan CC, Cover TL, Blaser MJ. Helicobacter pylori and gastric acid: biological and therapeutic implications. Gastroenterology. 1996;110:926–38.CrossRefPubMed
15.
go back to reference Kes P. Serum gastrin concentration in chronic renal failure. Acta Med Croatica. 1992;46(1):47–58.PubMed Kes P. Serum gastrin concentration in chronic renal failure. Acta Med Croatica. 1992;46(1):47–58.PubMed
16.
go back to reference Quintero E, Ohning GV, Del Rivero M, Wong HC, Walsh JH. Guth PH gastrin mediates the increase in gastric cell growth in uremic rats. Am J Physiol. 1995;268(4):586–91. Quintero E, Ohning GV, Del Rivero M, Wong HC, Walsh JH. Guth PH gastrin mediates the increase in gastric cell growth in uremic rats. Am J Physiol. 1995;268(4):586–91.
17.
go back to reference Quintero E, Kaunitz J, Nishizaki Y, De Giorgio R, Sternini C, Guth PH. Uremia increases gastric mucosal permeability and acid back-diffusion injury in the rat. Gastroenterology. 1992;103(6):1762–8.PubMed Quintero E, Kaunitz J, Nishizaki Y, De Giorgio R, Sternini C, Guth PH. Uremia increases gastric mucosal permeability and acid back-diffusion injury in the rat. Gastroenterology. 1992;103(6):1762–8.PubMed
18.
go back to reference Fallone CA, Mayrand S. Gastroesophageal reflux and hyperacidity in chronic renal failure. Perit Dial Int. 2001;21 Suppl 3:S295–9.PubMed Fallone CA, Mayrand S. Gastroesophageal reflux and hyperacidity in chronic renal failure. Perit Dial Int. 2001;21 Suppl 3:S295–9.PubMed
19.
go back to reference Collen MJ, Jensen RT. Idiopathic gastric acid hypersecretion. Comparison with Zollinger-Ellison syndrome. Dig Dis Sci. 1994;39(7):1434–40.CrossRefPubMed Collen MJ, Jensen RT. Idiopathic gastric acid hypersecretion. Comparison with Zollinger-Ellison syndrome. Dig Dis Sci. 1994;39(7):1434–40.CrossRefPubMed
20.
go back to reference Blonski WC, Katzka DA, Lichtenstein GR, Metz DC. Idiopathic gastric acid hypersecretion presenting as a diarrheal disorder and mimicking both Zollinger-Ellison syndrome and Crohn’s disease. Eur J Gastroenterol Hepatol. 2005;17(4):441–4.CrossRefPubMed Blonski WC, Katzka DA, Lichtenstein GR, Metz DC. Idiopathic gastric acid hypersecretion presenting as a diarrheal disorder and mimicking both Zollinger-Ellison syndrome and Crohn’s disease. Eur J Gastroenterol Hepatol. 2005;17(4):441–4.CrossRefPubMed
21.
go back to reference Reggoug S, Ropert A, Blayau M, Zeddini A, Dugast C, Péquin P, et al. Idiopathic gastric acid hypersecretion in a patient with MUTYH-associated polyposis. Am J Gastroenterol. 2009;104(10):2648–9. Reggoug S, Ropert A, Blayau M, Zeddini A, Dugast C, Péquin P, et al. Idiopathic gastric acid hypersecretion in a patient with MUTYH-associated polyposis. Am J Gastroenterol. 2009;104(10):2648–9.
22.
go back to reference Jin G, Westphalen CB, Hayakawa Y, Worthley DL, Asfaha S, Yang X, et al. Progastrin stimulates colonic cell proliferation via CCK2R- and β-arrestin-dependent suppression of BMP2. Gastroenterology. 2013;145(4):820–30.CrossRefPubMed Jin G, Westphalen CB, Hayakawa Y, Worthley DL, Asfaha S, Yang X, et al. Progastrin stimulates colonic cell proliferation via CCK2R- and β-arrestin-dependent suppression of BMP2. Gastroenterology. 2013;145(4):820–30.CrossRefPubMed
23.
go back to reference Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the national institutes of health and comparison with 2229 cases from the literature. Med (Baltimore). 2006;85(6):295–330.CrossRef Berna MJ, Hoffmann KM, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the national institutes of health and comparison with 2229 cases from the literature. Med (Baltimore). 2006;85(6):295–330.CrossRef
24.••
go back to reference Poitras P, Gingras MH, Rehfeld JF. The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol. 2012;10(2):199–202. This article provides recommendations for the management of gastric acid hypersecretion in patients with ZES.CrossRefPubMed Poitras P, Gingras MH, Rehfeld JF. The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol. 2012;10(2):199–202. This article provides recommendations for the management of gastric acid hypersecretion in patients with ZES.CrossRefPubMed
25.
go back to reference Shibata C, Funayama Y, Fukushima K, Ueno T, Kohyama A, Satoh K, et al. The glucagon provocative test for the diagnosis and treatment of Zollinger-Ellison syndrome. J Gastrointest Surg. 2008;12(2):344–9. Shibata C, Funayama Y, Fukushima K, Ueno T, Kohyama A, Satoh K, et al. The glucagon provocative test for the diagnosis and treatment of Zollinger-Ellison syndrome. J Gastrointest Surg. 2008;12(2):344–9.
26.
go back to reference Frucht H, Howard JM, Slaff JI, Wank SA, McCarthy DM, Maton PN, et al. Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study. Ann Intern Med. 1989;111(9):713–22. Frucht H, Howard JM, Slaff JI, Wank SA, McCarthy DM, Maton PN, et al. Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study. Ann Intern Med. 1989;111(9):713–22.
27.
go back to reference Ghosh T, Lewis DI, Axon ATR, Everett SM. Review article: methods of measuring gastric acid secretion. Aliment Pharmacol Ther. 2011;33(7):768–81.CrossRefPubMed Ghosh T, Lewis DI, Axon ATR, Everett SM. Review article: methods of measuring gastric acid secretion. Aliment Pharmacol Ther. 2011;33(7):768–81.CrossRefPubMed
28.•
go back to reference Chang JH, Choi MG, Yim DS, Cho YK, Park JM, Lee IS, et al. A novel placement method of the bravo wireless pH monitoring capsule for measuring intragastric pH. Dig Dis Sci. 2009;54(3):578–85. This article provides the approach to measuring gastric acid secretion in patients using a wireless approach. Chang JH, Choi MG, Yim DS, Cho YK, Park JM, Lee IS, et al. A novel placement method of the bravo wireless pH monitoring capsule for measuring intragastric pH. Dig Dis Sci. 2009;54(3):578–85. This article provides the approach to measuring gastric acid secretion in patients using a wireless approach.
29.••
go back to reference Oh DS, Wang HS, Ohning GV, Pisegna JR. Validation of a new endoscopic technique to assess acid output in Zollinger-Ellison syndrome. Clin Gastroenterol Hepatol. 2006;4(1):1467–73. This article provides a useful approach to the measurement of gastric acid secretion using standard endoscopic approaches. Oh DS, Wang HS, Ohning GV, Pisegna JR. Validation of a new endoscopic technique to assess acid output in Zollinger-Ellison syndrome. Clin Gastroenterol Hepatol. 2006;4(1):1467–73. This article provides a useful approach to the measurement of gastric acid secretion using standard endoscopic approaches.
30.••
go back to reference Weinstein DH, deRijke S, Chow CC, Foruraghi L, Zhao X, Wright EC, et al. A new method for determining gastric acid output using a wireless pH-sensing capsule. Aliment Pharmacol Ther. 2013;37(12):1198–209. This article provides an innovative approach to the measurement of gastric acid secretion in patients using the wireless pH sensing capsule.PubMedCentralCrossRefPubMed Weinstein DH, deRijke S, Chow CC, Foruraghi L, Zhao X, Wright EC, et al. A new method for determining gastric acid output using a wireless pH-sensing capsule. Aliment Pharmacol Ther. 2013;37(12):1198–209. This article provides an innovative approach to the measurement of gastric acid secretion in patients using the wireless pH sensing capsule.PubMedCentralCrossRefPubMed
31.
go back to reference Metz DC, Forsmark C, Lew EA, Starr JA, Soffer EF, Bochenek W, et al. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Am J Gastroenterol. 2001;96(12):3274–80.CrossRefPubMed Metz DC, Forsmark C, Lew EA, Starr JA, Soffer EF, Bochenek W, et al. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Am J Gastroenterol. 2001;96(12):3274–80.CrossRefPubMed
32.
go back to reference Lew EA, Pisegna JR, Starr JA, Soffer EF, Forsmark C, Modlin IM, et al. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology. 2000;118(4):696–704. Lew EA, Pisegna JR, Starr JA, Soffer EF, Forsmark C, Modlin IM, et al. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology. 2000;118(4):696–704.
33.
go back to reference Lau JYW, Sung JJ, Lee KK. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med. 2000;343:310–6.CrossRefPubMed Lau JYW, Sung JJ, Lee KK. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med. 2000;343:310–6.CrossRefPubMed
34.••
go back to reference Metz DC, Strader DB, Orbuch M, Koviack PD, Feigenbaum KM, Jensen RT. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther. 1993;7(6):597–610. This study provides the approach for using long term gastric acid suppression in patients with Zollinger-Ellison Syndrome. The authors investigated the use of omeprazole over a period of nine years. Metz DC, Strader DB, Orbuch M, Koviack PD, Feigenbaum KM, Jensen RT. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther. 1993;7(6):597–610. This study provides the approach for using long term gastric acid suppression in patients with Zollinger-Ellison Syndrome. The authors investigated the use of omeprazole over a period of nine years.
35.
go back to reference Pisegna JR, Sostek MB, Monyak JT, Miner PB Jr. Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults. Aliment Pharmacol Ther. 2008;27(6):483–90. Pisegna JR, Sostek MB, Monyak JT, Miner PB Jr. Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults. Aliment Pharmacol Ther. 2008;27(6):483–90.
36.
go back to reference Metz DC, Pisegna JR, Fishbeyn VA, Benya RV, Feigenbaum KM, Koviack PD, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology. 1992;103(5):1498–508.PubMed Metz DC, Pisegna JR, Fishbeyn VA, Benya RV, Feigenbaum KM, Koviack PD, et al. Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology. 1992;103(5):1498–508.PubMed
37.
go back to reference Hirschowitz BI, Simmons J, Mohnen J. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol. 2005;3(1):39–48.CrossRefPubMed Hirschowitz BI, Simmons J, Mohnen J. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clin Gastroenterol Hepatol. 2005;3(1):39–48.CrossRefPubMed
38.
go back to reference McArthur KE, Richardson CT, Barnett CC, Eshaghi N, Smerud MJ, McClelland RN, et al. Laparotomy and proximal gastric vagotomy in Zollinger-Ellison syndrome: results of a 16-year prospective study. Am J Gastroenterol. 1996;91(6):1104–11. McArthur KE, Richardson CT, Barnett CC, Eshaghi N, Smerud MJ, McClelland RN, et al. Laparotomy and proximal gastric vagotomy in Zollinger-Ellison syndrome: results of a 16-year prospective study. Am J Gastroenterol. 1996;91(6):1104–11.
39.
go back to reference Metz DC, Sostek MB, Ruszniewski P, Forsmark CE, Monyak J, Pisegna JR. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol. 2007;2648–2654. Metz DC, Sostek MB, Ruszniewski P, Forsmark CE, Monyak J, Pisegna JR. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol. 2007;2648–2654.
40.
go back to reference Metz DC, Soffer E, Forsmark CE, Cryer B, Chey W, Bochenek W, and Pisegna JR. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion. Am J Gastroenterol. 2003. 98(2). Metz DC, Soffer E, Forsmark CE, Cryer B, Chey W, Bochenek W, and Pisegna JR. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion. Am J Gastroenterol. 2003. 98(2).
41.
go back to reference Carswell CI, Goa KL. Rabeprazole: an update of its use in acid-related disorders. Drugs 2001;61(15):2327–56. Carswell CI, Goa KL. Rabeprazole: an update of its use in acid-related disorders. Drugs 2001;61(15):2327–56.
42.
go back to reference Norton JA. Intra-operative procedures to localize endocrine tumours of the pancreas and duodenum. Ital J Gastroenterol Hepatol. 1999;31(2):195–97. Norton JA. Intra-operative procedures to localize endocrine tumours of the pancreas and duodenum. Ital J Gastroenterol Hepatol. 1999;31(2):195–97.
43.
go back to reference Stewart CA, Termanini B, Sutliff VE, Corleto VD, Weber HC, Gibril F, et al. Management of the Zollinger-Ellison syndrome in pregnancy. Am J Obstet Gynecol. 1997;176(1):224–33.CrossRefPubMed Stewart CA, Termanini B, Sutliff VE, Corleto VD, Weber HC, Gibril F, et al. Management of the Zollinger-Ellison syndrome in pregnancy. Am J Obstet Gynecol. 1997;176(1):224–33.CrossRefPubMed
Metadata
Title
Gastric Hypersecretory States: Investigation and Management
Authors
Jennifer Phan, MD
Jihane N. Benhammou, MD
Joseph R. Pisegna, MD
Publication date
01-12-2015
Publisher
Springer US
Published in
Current Treatment Options in Gastroenterology / Issue 4/2015
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI
https://doi.org/10.1007/s11938-015-0065-8

Other articles of this Issue 4/2015

Current Treatment Options in Gastroenterology 4/2015 Go to the issue

Stomach (C Howden, Section Editor)

Detection and Management of Early Gastric Cancer

Motility (T Lembo, Section Editor)

Neuroenteric Stimulation for Gastroparesis

Motility (T Lembo, Section Editor)

Novel Therapies in IBS-D Treatment

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine